19 drugs to benefit from US FDA 'infectious disease' designation
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has as of 11 July granted 19 requests from drug makers seeking a qualified infectious disease product (QIDP) designation for their investigational product – a status that could garner the experimental medicine an additional five years of market exclusivity if approved1.